Classes
DEA Class; Rx
Common Brand Names; Isoptin SR, Calan SR, Covera HS, Isoptin, Isoptin IV, Calan, Verap, Verapamil SR, Verelan, Verelan PM
- Antidysrhythmics, IV;
- Calcium Channel Blockers;
- Calcium Channel Blockers, Non-dihydropyridine
Description
Indications
Indicated for the treatment of variant angina (Prinzmetal angina), unstable angina, and chronic stable angina.
Contraindications
Hypersensitivity to verapamil or other calcium channel blockers
Cardiogenic shock
Congestive heart failure
Symptomatic hypotension
Sick sinus syndrome (unless permanent pacemaker in place)
2°/3° AV block (unless permanent pacemaker in place)
Adverse Effects
- Headache
- Gingival hyperplasia
- Constipation (9%)
- Dizziness (4%)
- Hypotension (4%)
- Dyspepsia (3%)
- Nausea (3%)
- Edema (2%)
- Rash (2%)
- Increased liver enzymes (1%)
- Sleep disturbance (1%)
- Dyspnea
- Abnormal ECG
- Hypertension
- Elevated liver function test results
- Asthenia
Warnings
Aortic stenosis
Atrial fibrillation/flutter with accessory bypass tract
1° AV block
Hypertrophic cardiomyopathy (eg, idiopathic hypertrophic subaortic stenosis)
Hypotension (initially or after dose increases)
Exacerbation of angina (during initiation of treatment, after dose increase, or after withdrawal of beta blocker)
Neuromuscular transmission defects; may exacerbate myasthenia gravis
Hepatic or renal impairment
Persistent progressive dermatologic reactions
Generic products may not be bioequivalent
Do not prescribe Covera-HS or Verelan PM for shift workers
Concurrent beta-blocker therapy
Concurrent ivabradine therapy
Slows AV conduction; use cautiously with beta blockers
Hypotension and bradyarrhythmias observed with concurrent use of other CYP3A4 substrates (eg, cyclosporine, telithromycin) because of competitive metabolism
Coadministration with CYP3A4 inhibitors (eg, erythromycin, itraconazole) may decrease metabolism and thus increase toxicity
Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with concurrent use of clonidine with verapamil; monitor heart rate if coadministered
Verapamil is no longer part of Pediatric Advanced Life Support tachyarrhythmia algorithm
Potential toxic dose in patients <6 years old: 15 mg/kg
Pregnancy and Lactation
Pregnancy category: C
Lactation: Distributed in milk; nursing infant doses range from <0.01% to 0.1% of mother’s dose; manufacturer suggests refraining from nursing (though American Academy of Pediatrics committee states that drug is compatible with nursing)
Maximum Dosage
480 mg/day PO for Calan, Calan SR, Isoptin, Isoptin SR, Verelan, or generic equivalents; 400 mg/day PO for Verelan PM; 540 mg/day PO for Covera-HS; for most approved indications.
480 mg/day PO for Calan, Calan SR, Isoptin, Isoptin SR, Verelan; 400 mg/day PO for Verelan PM; 540 mg/day PO for Covera-HS; for most approved indications.
Safety and efficacy have not been established; however, doses up to 8 mg/kg/day PO have been reported in pediatric patients. Do not exceed the adult maximum dose for a given dosage form.
Safety and efficacy have not been established; however, doses up to 8 mg/kg/day PO have been reported in pediatric patients. Do not exceed the adult maximum dose for a given dosage form.
How supplied
Verapamil hydrochloride
injectable solution
- 2.5mg/mL
tablet
- 40mg
- 80mg
- 120mg
tablet/capsule, extended release
- 100mg
- 120mg
- 180mg
- 200mg
- 240mg
- 300mg
- 360mg